1. Home
  2. DELL vs SNY Comparison

DELL vs SNY Comparison

Compare DELL & SNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Dell Technologies Inc.

DELL

Dell Technologies Inc.

HOLD

Current Price

$179.47

Market Cap

103.7B

Sector

Technology

ML Signal

HOLD

Logo Sanofi ADS

SNY

Sanofi ADS

HOLD

Current Price

$48.16

Market Cap

107.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DELL
SNY
Founded
1984
1994
Country
United States
France
Employees
N/A
74846
Industry
Computer Manufacturing
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
103.7B
107.3B
IPO Year
2013
N/A

Fundamental Metrics

Financial Performance
Metric
DELL
SNY
Price
$179.47
$48.16
Analyst Decision
Buy
Buy
Analyst Count
16
5
Target Price
$172.07
$58.00
AVG Volume (30 Days)
7.5M
2.9M
Earning Date
05-28-2026
04-23-2026
Dividend Yield
1.14%
3.36%
EPS Growth
36.05
N/A
EPS
8.68
N/A
Revenue
$113,538,000,000.00
N/A
Revenue This Year
$26.15
$3.86
Revenue Next Year
$8.65
$5.64
P/E Ratio
$21.26
$6.14
Revenue Growth
18.80
N/A
52 Week Low
$80.74
$43.32
52 Week High
$191.37
$55.73

Technical Indicators

Market Signals
Indicator
DELL
SNY
Relative Strength Index (RSI) 58.66 62.53
Support Level $116.60 $46.88
Resistance Level $186.39 $48.88
Average True Range (ATR) 8.17 0.74
MACD -0.37 0.14
Stochastic Oscillator 66.11 95.20

Price Performance

Historical Comparison
DELL
SNY

About DELL Dell Technologies Inc.

Dell Technologies is a broad information technology vendor, primarily supplying hardware to enterprises. It focuses on premium and commercial personal computers, as well as enterprise on-premises data center hardware. It holds top-three shares in its core markets of personal computers, peripheral displays, mainstream servers, and external storage. Dell has a robust ecosystem of component and assembly partners and also relies heavily on channel partners to fulfill its sales.

About SNY Sanofi ADS

Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for over 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.

Share on Social Networks: